Life Science Webinars

31. Tortoise Or Hare? How Biosafety Assurance Can Be Both Rapid And Purposeful Getting You To The Finish Line First. 2/24/2021

    In this webinar we will discuss how the advancement of bioprocessing and the rise of novel treatment modalities such as viral vectors, as well as the urgent need for SARS-CoV-2 treatments and vaccines have driven the industry to adopt rapid alternatives. By illustrating the reasons behind the move to faster methods and discussing the wider benefits these can bring we hope to do our bit to drive change within this change resistant environment, and help our customers win the race to market.

32. Similar Enough Product Characterization To Support Process Changes And Biosimilar Development 2/24/2021

    Small differences in manufacturing conditions can have dramatic effects on a product’s structure and biological activity. Characterization is essential to understand the impact following process changes and successful biosimilar development. We will provide best approaches for comparability studies.

33. How Biosafety Testing Will Evolve To Meet The Needs Of Biologics Manufacturers Tomorrow 2/24/2021

    The pressure to shorten delivery times and reduce costs for biologics such as mAbs are driving an evolution in the biomanufacturing space. Ironically, where we see almost daily innovation in production technologies, many of the methods used for biosafety testing are decades old. In this talk we will explore how new methods can be used to accelerate biosafety testing today.

34. Evaluating Viral Clearance For Continuous Processes 2/24/2021

    Is viral clearance a hurdle to implementing continuous processing? We’ll share virus spiking alternatives that may pave the way for effectively evaluating viral clearance by chromatography steps in a continuous process.

35. Effect Of Product Concentration On Continuous Parvovirus Retentive Filtration 2/23/2021

    This video illustrates how careful process development and system design can address higher-concentration intermediate challenges and optimize virus filtration processes.

36. Biosafety In Gene Therapy: Applying The Latest Regulatory Guidance For RCL Testing 2/23/2021

    The use of lentivirus vectors to produce groundbreaking gene therapies is on the rise. Ensuring the biosafety and quality of these vectors is achieved through a multi-tiered testing approach. For lentivirus-based therapies, generation of replication competent particles is a potential risk. While improvements in design and manufacturing have decreased the probability of producing replication competent viruses, regulatory agencies provide guidelines to test for their presence at multiple stages in production.

37. Key Challenges When Selecting Media For Media Fill Tests 2/19/2021

    In this 10-minute quick learning tutorial our expert guides you through the main challenges for aseptic manufacturers when selecting a medium for media fill tests or aseptic process simulations and how to overcome these challenges. You will learn why our products are exactly what you need to perform aseptic process simulations. We offer reliable granulated or ready-to-use media that are easy to implement in your existing processes.

38. Selecting The Right Media For Your Aseptic Process Simulations 2/19/2021

    In pharmaceutical manufacturing, product safety is vital. Aseptic processing simulations or media fill tests are performed to ensure that your facility produces microbiologically safe parenteral drugs. In this webinar, our media fill experts will give an overview of what to consider when selecting media for aseptic process simulations.

39. Scale-Up Of Antibody Production: From Bench To Pilot/Production 2/11/2021

    Here, we detail techniques for the scale-up of an antibody production workflow using CHO cells and illustrate how novel scale-up assist software supports scale-up strategy design.

40. Panel Discussion: Streamlining Biologics Scale-Up 2/11/2021

    Streamlining the transfer of an upstream bioprocess from research to production scale is critical for reducing development costs and time to market. In this panel discussion, Winston Wong (Eppendorf Americas), Klaus Ferber (Eppendorf AG), Ben Asher (Thermo Fisher Scientific) and John Shyu (Corning Life Sciences) discuss scale-up challenges from an economical, operational, and application-related point of view.